Company research
Vera Therapeutics, Inc.
CIK 1831828Updated Sep 27, 2026
SecurityVERA · NASDAQ · equity
VERA price & chart
Loading TradingView…
NASDAQ:VERA on TradingView ↗About the company
Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics’ flagship commercial product is TRUTAKNA (atacicept-vymj), a BAFF and APRIL inhibitor indicated to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California. To learn more, visit www.veratx.com.
In the news
No coverage from other publishers is available.
Recent filings
4 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
4 filing
144 filing
SCHEDULE 13G/A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 734,733,000Source | 655,681,000Source | 175,546,000Source | 131,435,000Source |
| Property, Plant and Equipment, NetUSD | 1,374,000Source | 960,000Source | 92,000Source | 51,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 354,725,000Source | 92,646,000Source | 45,681,000Source | 43,459,000Source |
| Assets, CurrentUSD | 728,883,000Source | 651,218,000Source | 172,023,000Source | 125,698,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 14,294,000Source | 10,366,000Source | 11,307,000Source | 11,045,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,923,000Source | 3,372,000Source | 2,949,000Source | 5,173,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 130,212,000Source | 78,526,000Source | 73,861,000Source | 54,527,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 71,000Source | 64,000Source | 44,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -760,865,000Source | -461,250,000Source | -309,102,000Source | -213,112,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 786,000Source | 393,000Source | 251,000Source | -224,000Source |
| Stockholders' Equity Attributable to ParentUSD | 604,521,000Source | 577,155,000Source | 101,685,000Source | 76,908,000Source |
| Additional Paid in Capital, Common StockUSD | 1,364,529,000Source | 1,037,948,000Source | 410,492,000Source | 290,216,000Source |
| Liabilities and EquityUSD | 734,733,000Source | 655,681,000Source | 175,546,000Source | 131,435,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 53,455,000Source | 25,371,000Source | 22,303,000Source | 25,600,000Source |
| Operating Lease, Liability, CurrentUSD | 549,000Source | 1,483,000Source | 2,436,000Source | 2,645,000Source |
| Accounts Payable, CurrentUSD | 21,898,000Source | 7,665,000Source | 11,118,000Source | 11,991,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,919,000Source | 2,468,000Source | 1,395,000Source | 3,831,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 31,008,000Source | 16,223,000Source | 8,749,000Source | 10,964,000Source |
| Long-term DebtUSD | 74,838,000Source | 50,687,000Source | 49,877,000Source | 24,810,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 468,000Source | 105,000Source | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 37,926,000Source | 20,802,000Source | 11,493,000Source | 8,887,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 13,910,000Source | -3,453,000Source | -873,000Source | 10,606,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -241,104,000Source | -134,679,000Source | -92,181,000Source | -67,596,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 194,286,000Source | -425,029,000Source | -39,431,000Source | -70,552,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 630,000Source | 972,000Source | 63,000Source | 62,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 0Source | 13,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 308,897,000Source | 606,673,000Source | 133,541,000Source | 101,933,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 262,079,000Source | 46,965,000Source | 1,929,000Source | -36,215,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 354,725,000Source | 92,646,000Source | 45,681,000Source | 43,752,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 6,720,000Source | 6,652,000Source | 3,352,000Source | 895,000Source |
| Income Taxes Paid, NetUSD | 17,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 37,926,000Source | 20,802,000Source | 11,493,000Source | 8,887,000Source |
| Depreciation, Amortization and Accretion, NetUSD | — | — | -4,086,000Source | -846,000Source |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | -47,000Source | -809,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | -47,000Source | -809,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | 2,700,000Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 100,217,000Source | 40,998,000Source | 23,787,000Source | 21,910,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | — | — |
| Income Tax Expense (Benefit)USD | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| InterestExpenseNonoperatingUSD | 7,531,000Source | 7,626,000Source | — | — |
| Investment Income, InterestUSD | 24,479,000Source | 20,714,000Source | 7,979,000Source | 1,750,000Source |
| Net Income (Loss) Attributable to ParentUSD | -299,615,000Source | -152,148,000Source | -95,990,000Source | -89,056,000Source |
| Nonoperating Income (Expense)USD | 15,859,000Source | 15,023,000Source | 6,023,000Source | 1,848,000Source |
| Operating ExpensesUSD | 315,473,000Source | 167,170,000Source | 102,012,000Source | 90,903,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 2,000,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | 393,000Source | 142,000Source | 475,000Source | -224,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -315,473,000Source | -167,170,000Source | -102,012,000Source | -90,903,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -299,614,000Source | -152,147,000Source | -95,989,000Source | -89,055,000Source |
| Income Tax Expense (Benefit)USD | 1,000Source | 1,000Source | 1,000Source | 1,000Source |
| Net Income (Loss) Attributable to ParentUSD | -299,615,000Source | -152,148,000Source | -95,990,000Source | -89,056,000Source |
| Earnings Per Share, BasicUSD per share | -4.66Source | -2.75Source | -2.25Source | -3.35Source |
| Earnings Per Share, DilutedUSD per share | -4.66Source | -2.75Source | -2.25Source | -3.35Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 64,233,814Source | 55,326,680Source | 42,707,072Source | 26,570,676Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 64,233,814Source | 55,326,680Source | 42,707,072Source | 26,570,676Source |
| Interest Expense (non-operating)USD | 7,531,000Source | 7,626,000Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | — | 1,000Source | 1,000Source | 1,000Source |
| General and Administrative ExpenseUSD | 100,217,000Source | 40,998,000Source | 23,787,000Source | 21,910,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -299,614,000Source | -152,147,000Source | -95,989,000Source | -89,055,000Source |
| Interest ExpenseUSD | — | — | 3,786,000Source | 992,000Source |
| Investment Income, InterestUSD | 24,479,000Source | 20,714,000Source | 7,979,000Source | 1,750,000Source |
| Nonoperating Income (Expense)USD | 15,859,000Source | 15,023,000Source | 6,023,000Source | 1,848,000Source |
| Operating ExpensesUSD | 315,473,000Source | 167,170,000Source | 102,012,000Source | 90,903,000Source |
| Other IncomeUSD | -1,089,000Source | 1,935,000Source | 1,877,000Source | 1,899,000Source |
| Research and Development ExpenseUSD | 215,256,000Source | 126,172,000Source | 78,225,000Source | 68,993,000Source |
Filing attachments
d32300dex991.htm · 8-K · 2026-09-15
EX-99.1 2 d32300dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Vera Therapeutics Announces TRUTAKNA ™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease progression benefits. ──────────…
Read attachment ↗d32300dex992.htm · 8-K · 2026-09-15
EX-99.2 3 d32300dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Corporate Presentation Sep temb er 2026 © 2026 Vera Therapeutics, Inc. Corporate Presentation Forward -looking statements Disclaime r This material has b een mad e availab le to you with the consent of Vera Therap eutics, Inc. ( we, us, our, or the Comp any ). State me nts in this p re se ntation that are not state me nts of historical fact are forward -looking state me nts within the me aning of the Private Se curitie s Litig ation R…
Read attachment ↗vera-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 vera-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results • TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression. • Alignment with FDA on earlier ORIGIN 3 final efficacy analysis to support potential full approval for TRUTAKNA in adults with IgAN; results expected in Q3 2026. • Anticip…
Read attachment ↗vera-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 vera-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results • U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 • On track for U.S. commercial launch of atacicept in mid-2026, pending regulatory ap…
Read attachment ↗